Latest Clinical News

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (07-26-2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State... Continue Reading

Chimeric Antigen Receptor (CAR) T-cell Immunotherapy – Crafting a Better T Cell for Immunotherapy (07-25-2017)

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell Acute Lymphoblastic Leukemia.  CAR-T also shows promise in ALL, CLL, other B-cell malignancies, and other... Continue Reading

Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas (07-24-2017)

Donald M. O’Rourke, MD Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor... Continue Reading

Delaying Lymph Node Biopsy After Melanoma Diagnosis Does Not Affect Survival Rates (07-20-2017)

A lymph node biopsy occurring more than 30 days after diagnosis is unlikely to have an adverse effect on the patient’s overall prognosis Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn’t adversely impact long-term... Continue Reading

New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style (07-19-2017)

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA... Continue Reading

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer (07-18-2017)

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the... Continue Reading

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma (07-18-2017)

A clinical trial evaluating Opdivo  (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survival in... Continue Reading

Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know (07-17-2017)

The purpose of precision cancer medicine is not to categorize or classify cancers solely by site of origin, but to define the genomic alterations in the cancer’s DNA that are driving that specific cancer.  Precision cancer medicine utilizes molecular... Continue Reading

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift (07-13-2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated... Continue Reading

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (07-12-2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become... Continue Reading

Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (07-12-2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing... Continue Reading

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising (07-11-2017)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking... Continue Reading

Next Page »